Genetic Technologies Limited
GNTLF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $5 | $4 | $5 |
| % Growth | -91.4% | 21.2% | -12.7% | – |
| Cost of Goods Sold | $0 | $2 | $6 | $6 |
| Gross Profit | $0 | $3 | -$2 | -$1 |
| % Margin | 100% | 58.3% | -50% | -27% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $9 | $0 | $1 |
| SG&A Expenses | $1 | $6 | $2 | $4 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | -$0 | -$1 |
| Operating Expenses | $1 | $6 | $2 | $3 |
| Operating Income | -$1 | -$3 | -$5 | -$5 |
| % Margin | -194.6% | -72.3% | -130.4% | -101.1% |
| Other Income/Exp. Net | -$2 | -$2 | -$1 | -$2 |
| Pre-Tax Income | -$3 | -$6 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$4 | -$6 | -$6 | -$6 |
| % Margin | -987.2% | -116.6% | -162.2% | -138.8% |
| EPS | -0.021 | -0.038 | -0.053 | -0.065 |
| % Growth | 43.6% | 29.2% | 18.4% | – |
| EPS Diluted | -0.021 | -0.038 | -0.053 | -0.065 |
| Weighted Avg Shares Out | 193 | 149 | 121 | 97 |
| Weighted Avg Shares Out Dil | 144 | 149 | 121 | 97 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$5 | -$2 | -$6 |
| % Margin | -321.6% | -110.5% | -51.6% | -131.1% |